

Approved by:



CERTIFICATE

2025

Teilgemeinschaftspraxis Molekularpathologie Südbayern
Giesinger Bahnhofplatz 2
81539 München
Germany

has successfully completed the proficiency test

Mammakarzinom: HER2 / Breast Carcinoma: HER2 Split 2 (ISH)

(Trial Period 11.08.2025 - 29.08.2025)

Berlin, November 10, 2025

Prof. Dr. med. Claudia Wickenhauser
Quality in Pathology - QuIP GmbH

Thomas Pilz, Managing Director
Quality in Pathology - QuIP GmbH

Lead panel institute of the proficiency test:
Prof. Dr. med. Hans H. Kreipe, Medizinische Hochschule Hannover

This certificate includes the separate individual evaluation of the test and the corresponding proficiency test report, the evaluation criteria can be found in the proficiency test report under point 3.2.

This proficiency test was organized by:
Qualitätssicherungs-Initiative Pathologie QuIP GmbH /
Reinhardtstr. 1 / 10117 Berlin / office@quip.eu / www.qualityinpathology.com

